ArticleJournal of internal medicine2026
Clinical profiles associated with rapidly progressive interstitial lung disease in antisynthetase syndrome: A multicentric cohort study (TYPASS study).
Article in Journal of internal medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Clinical profiles associated with rapidly progressive interstitial lung disease in antisynthetase syndrome: A multicentric cohort study (TYPASS study).Journal of internal medicine · 2026Article
- Case Report: Acute interstitial pneumonia as the initial presentation of Anti-EJ antisynthetase syndrome: a case of severe respiratory failure with rapid response to cyclophosphamide.Frontiers in immunology · 2026Article
- Distinct phenotypic clusters associated with progressive pulmonary fibrosis in anti-synthetase syndrome-associated interstitial lung disease.Frontiers in immunology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesTo assess factors associated with rapidly progressive interstitial lung disease (ILD) (RP-ILD) at time of ILD diagnosis in a multicentric retrospective cohort study of antisynthetase syndrome (ASyS). We used a complementary unsupervised approach, hierarchical clustering, to delineate distinct phenotypes among ASyS patients with ILD.
methodsA total of 132 patients with ASyS, defined according to the 2024 ACR/European Alliance of Associations for Rheumatology (EULAR) ASyS classification criteria, and ILD, diagnosed by CT scan, were included. RP-ILD was defined by the presence of respiratory failure at ILD diagnosis or rapid ILD progression during the first 3 months.
resultsIn our study, 39% of patients had RP-ILD at ILD diagnosis. Multivariate logistic regression analysis with cluster-robust SE identified the factors associated with RP-ILD at ILD diagnosis as male sex (aOR = 9.7 [1.6-59.5], p = 0.006), fever (aOR = 128 [12.6-1300], p < 0.001), organizing pneumonia (OP) pattern (aOR = 66.8 [3.4-1316], p = 0.006), and pleural effusion (aOR = 20.2 [1.1-373], p = 0.04), whereas RP-ILD was associated with lower likelihood of severe muscle disease (aOR = 0.004 [0.0001-0.13], p = 0.002). Clustering analysis identified four distinct groups: Cluster 1 (n = 62) included patients with systemic presentation, non-RP-ILD at ILD diagnosis, and anti-Jo-1 antibodies with good prognosis; Cluster 2 (n = 40) included older age patients with more RP-ILD at ILD diagnosis, pleuropericarditis, and a higher mortality rate.
conclusionFever, pleural effusion, and OP pattern were independently associated with RP-ILD in ASyS patients. Unsupervised cluster analysis identified a severe inflammatory phenotype in ASyS patients with ILD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.